Diabetic Under 70 (Diabetics Below 70) - Clinical Trial...

Diabetic Under 70 (Diabetics Below 70)

Diabetic Under 70 (Diabetics Below 70)
This study is currently recruiting participants.
Verified by AstraZeneca, August 2007
Sponsored by: AstraZeneca

Information provided by: AstraZeneca
ClinicalTrials.gov Identifier: NCT00516204

Purpose
A screening project of diabetics with a very high cardiovascular risk (e.g. diabetes plus coronary heart disease) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is <70mg/dl for such patients with very high risk) are screened. The doctors therapy decisions after the screening will be documented and 8-10 weeks later the lipid profile of each patient will be evaluated again. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.

Condition Intervention
Diabetes
Hyperlipidemia
Atherosclerosis
Drug: Any cholesterol-lowering drug

MedlinePlus related topics: Cholesterol Diabetes Heart Diseases
Drug Information available for: Cholest-5-en-3-ol (3beta)-
U.S. FDA Resources
Study Type:Observational
Study Design:Screening, Longitudinal, Defined Population, Prospective Study
Official Title:Diabetic Under 70 (Diabetics Below 70)

Further study details as provided by AstraZeneca:

Estimated Enrollment:1400
Study Start Date:July 2007


Eligibility
Ages Eligible for Study:18 Years and older
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No
Criteria
Inclusion Criteria:

Diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PAVK, etc.) who already receive cholesterol-lowering therapy
Exclusion Criteria:

Diabetics w/o CVD; diabetics who do not receive cholesterol-lowering therapy
Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00516204

Contacts
Contact: AstraZeneca Austria Clinical, Study Information 43 1 71131 277 paul.grundtner@astrazeneca.com

Locations
Austria
Research Site Recruiting
Vienna, Austria

Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Michael Roden, MD Chairs of the Austrian Diabetes Society

More Information

Study ID Numbers:NIS-CAT-CRE-2007/3
First Received:August 14, 2007
Last Updated:September 27, 2007
ClinicalTrials.gov Identifier:NCT00516204 [history]
Health Authority:Not required for this study:

Keywords provided by AstraZeneca:
Hyperlipidemia
Diabetics
NIS
Diabetics with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PAVK, etc.)

Study placed in the following topic categories:
Atherosclerosis
Arterial Occlusive Diseases
Heart Diseases
Hyperlipidemias
Metabolic Diseases
Diabetes Mellitus
Vascular Diseases
Constriction, Pathologic
Arteriosclerosis
Coronary Disease
Carotid Stenosis
Metabolic disorder
Coronary Artery Disease
Dyslipidemias
Lipid Metabolism Disorders

Additional relevant MeSH terms:
Cardiovascular Diseases